Insider · CIK 0001184334
Robert E Conway
Files at ORKA (ARCA biopharma, Inc.), ALPN (ALPINE IMMUNE SCIENCES, INC.). First filing -, latest -.
In brief
Robert E Conway files SEC Form 4 as director at ORKA (ARCA biopharma, Inc.), and also at ALPN (ALPINE IMMUNE SCIENCES, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Robert E Conway has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Common Stockindirect: By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | -50,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -2,868 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -3,075 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -1,912 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -7,650 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -10,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -10,000 | - | - | 0 | May 20, 2024 |
| May 20, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | DDisposition to issuer Stock Option (Right to buy)derivative | -17,500 | - | - | 0 | May 20, 2024 |
| Jan 30, 2024 | ORKA ARCA biopharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Jan 31, 2024 |
| Jan 2, 2024 | ALPN ALPINE IMMUNE SCIENCES, INC. | AGrant or award Stock Option (Right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jan 4, 2024 |
| Dec 15, 2022 | ORKA ARCA biopharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Dec 19, 2022 |
Questions about Robert E Conway
Answered from the filings on this page, as of the latest one.
Is Robert E Conway buying or selling?
Robert E Conway has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Robert E Conway's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Robert E Conway has 0.
Where does Robert E Conway file Form 4?
Robert E Conway has filed Form 4 at ORKA (ARCA biopharma, Inc.); ALPN (ALPINE IMMUNE SCIENCES, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.